Literature DB >> 21185823

Role of prostanoid IP and EP receptors in mediating vasorelaxant responses to PGI2 analogues in rat tail artery: Evidence for Gi/o modulation via EP3 receptors.

Nelson N Orie1, Lucie H Clapp.   

Abstract

Prostanoid IP receptors coupled to Gs are thought to be the primary target for prostacyclin (PGI(2)) analogues. However, these agents also activate prostanoid EP(1-4) receptor subtypes to varying degrees, which are positively (EP(2/4)) or negatively (EP(3)) coupled to adenylate cyclase through Gs or Gi, respectively. We investigated the role of these receptors in modulating relaxation to PGI(2) analogues cicaprost, iloprost and treprostinil in pre-contracted segments of rat tail artery. Prostanoid IP (RO1138452), EP(4) (GW627368X), EP(3) (L-798106), EP(1-3) (AH6809), and EP(1) (SC-51322) receptor antagonists were used to determine each receptor contribution. The role of G(i/o) was investigated using pertussis toxin (PTX), while dependence on cAMP was determined using adenylate cyclase (2'5'dideoxyadenosine, DDA) and protein kinase A (2'-O-monobutyryladenosine- 3',5'-cyclic monophosphorothioate, Rp- isomer, Rp-2'-O-MB-cAMPS) inhibitors, and by measurement of tissue cAMP. All analogues caused relaxation which was significantly (P<0.01) inhibited by RO1138452; with maximum response to cicaprost, iloprost and treprostinil reduced by 51%, 66% and 37%, respectively. GW627368X had no effect when used alone, but in combination with RO1138452, caused a rightward shift of the curves for cicaprost and iloprost but not treprostinil. PTX treatment potentiated relaxation to all 3 analogues (P<0.01), as did L798106 and AH6809 but not SC-51322. Basal cAMP levels were higher in PTX-treated tissues and DDA- and Rp-2'-O-MB-cAMPs--sensitive responses increased to analogue concentrations <0.1μM. In conclusion, prostanoid EP(3) receptors via G(i/o) negatively modulate prostanoid IP receptor-mediated relaxation to cicaprost, iloprost and treprostinil. However, other pathways contribute to analogue-induced vasorelaxation, the nature of which remains unclear for treprostinil.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21185823     DOI: 10.1016/j.ejphar.2010.12.005

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

1.  EP3 receptor deficiency attenuates pulmonary hypertension through suppression of Rho/TGF-β1 signaling.

Authors:  Ankang Lu; Caojian Zuo; Yuhu He; Guilin Chen; Lingjuan Piao; Jian Zhang; Bing Xiao; Yujun Shen; Juan Tang; Deping Kong; Sara Alberti; Di Chen; Shenkai Zuo; Qianqian Zhang; Shuai Yan; Xiaochun Fei; Fei Yuan; Bin Zhou; Shengzhong Duan; Yu Yu; Michael Lazarus; Yunchao Su; Richard M Breyer; Colin D Funk; Ying Yu
Journal:  J Clin Invest       Date:  2015-02-09       Impact factor: 14.808

2.  Apolipoprotein E favours the blunting by high-fat diet of prostacyclin receptor activation in the mouse aorta.

Authors:  Yanhua Cheng; Paul M Vanhoutte; Susan W S Leung
Journal:  Br J Pharmacol       Date:  2018-07-22       Impact factor: 8.739

3.  Hypoactivity of rat detrusor muscle in a model of cystitis: exacerbation by non-selective COX inhibitors and amelioration by a selective DP1 receptor antagonist.

Authors:  Wesam Bassiouni; Tahia Daabees; Xavier Norel; Amira M Senbel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-12-14       Impact factor: 3.000

Review 4.  Distinct roles of central and peripheral prostaglandin E2 and EP subtypes in blood pressure regulation.

Authors:  Tianxin Yang; Yaomin Du
Journal:  Am J Hypertens       Date:  2012-06-14       Impact factor: 2.689

5.  Adenosine A(1) and prostaglandin E receptor 3 receptors mediate global airway contraction after local epithelial injury.

Authors:  Jian Zhou; Martha B Alvarez-Elizondo; Elliot Botvinick; Steven C George
Journal:  Am J Respir Cell Mol Biol       Date:  2012-12-06       Impact factor: 6.914

6.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

7.  Iloprost improves ventricular function in the hypertrophic and functionally impaired right heart by direct stimulation.

Authors:  Sarah Holmboe; Asger Andersen; Mads D Vildbrad; Jan M Nielsen; Steffen Ringgaard; Jens E Nielsen-Kudsk
Journal:  Pulm Circ       Date:  2013-12       Impact factor: 3.017

8.  Prostaglandin E2 inhibits neutrophil extracellular trap formation through production of cyclic AMP.

Authors:  Kyosuke Shishikura; Takahiro Horiuchi; Natsumi Sakata; Duc-Anh Trinh; Ryutaro Shirakawa; Tomohiro Kimura; Yujiro Asada; Hisanori Horiuchi
Journal:  Br J Pharmacol       Date:  2015-12-16       Impact factor: 8.739

9.  Intracellular prostaglandin E2 contributes to hypoxia-induced proximal tubular cell death.

Authors:  Ana B Fernández-Martínez; Francisco J Lucio-Cazaña; Coral García-Pastor; Selma Benito-Martínez; Ricardo J Bosch
Journal:  Sci Rep       Date:  2021-03-29       Impact factor: 4.379

10.  Putative role of prostaglandin receptor in intracerebral hemorrhage.

Authors:  Shekher Mohan; Abdullah S Ahmad; Alexander V Glushakov; Chase Chambers; Sylvain Doré
Journal:  Front Neurol       Date:  2012-10-22       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.